US4479957A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of vindesine in treating acute lymphatic leukemia and _other susceptible neoplasms
Assignee: Eli Lilly and Co
•
Filing: 1981-04-02
•
Granted: 1984-10-30
•
Expires: 2001-04-02
Abstract
Abstract This invention relates to a method of treating neoplasms which comprises administering to a mammal suffering from a vindesinesusceptible neoplasm selected from the group consisting of acute lymphatic leukemia, acute granulocytic leukemia, chronic myeloid leukemia, non-small cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma, malignant melanoma carcinoma of the breast, esophageal carcinoma and testicular carcinoma an anti-neoplastically-effective amount of vindesine or a pharmaceutically-acceptable acid addition salt thereof.
Inventors
- 👤 George J. Cullinan
- 👤 Koert Gerzon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:10
CPC Classifications
C; C07; C07D; C07D519/00; C07D519/04
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
38 words
A pharmaceutical preparation in dosage unit form adapted for intravenous administration comprising per dosage unit an effective amount within the range 1 to 10 mg/ml of vindesine or a pharmaceutically-acceptable acid addition salt plus a pharmaceutical excipient thereof.
Claim 2
Dependent Claim
38 words
A pharmaceutical preparation in dosage unit form adapted for intravenous administration comprising per dosage unit an effective amount within the range 1 to 10 mg/ml of vindesine or a pharmaceutically-acceptable acid addition salt plus a pharmaceutical excipient thereof.
Claim 3
Dependent Claim
16 words
A dosage form according to claim 1 in which vindesine is present as the sulfate salt.
Claim 4
Independent Claim
62 words
The method of treating neoplasms which comprises administering to a mammal suffering from a vindesine-susceptible neoplasm selected from the group consisting of acute lymphatic leukemia, acute granulocytic leukemia, chronic myeloid leukemia, non-small cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma, malignant melanoma, carcinoma of the breast, esophageal carcinoma and testicular carcinoma an anti-neoplastically-effective amount of vindesine or a pharmaceutically-acceptable acid addition salt thereof.
Claim 5
Independent Claim
62 words
The method of treating neoplasms which comprises administering to a mammal suffering from a vindesine-susceptible neoplasm selected from the group consisting of acute lymphatic leukemia, acute granulocytic leukemia, chronic myeloid leukemia, non-small cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma, malignant melanoma, carcinoma of the breast, esophageal carcinoma and testicular carcinoma an anti-neoplastically-effective amount of vindesine or a pharmaceutically-acceptable acid addition salt thereof.
Claim 6
Dependent Claim
12 words
A method according to claim 3 in which vindesine monosulfate is used.
Claim 7
Dependent Claim
28 words
A method according to claim 3 in which vindesine or a salt thereof is administered at a dose level in the range 0.1-1 mg/kg of mammalian body weight.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-10-30 | 1988-04-30 | 1988-10-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-10-30 | 1992-04-30 | 1992-10-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-10-30 | 1996-04-30 | 1996-10-30 | $7700.00 | Window Closed / Lapsed |